All News

    Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans

    October 17th 2024

    By Skylar Jeremias

    Article

    Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.

    Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges

    October 16th 2024

    By Skylar Jeremias

    Article

    The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.

    Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review

    October 15th 2024

    By Skylar Jeremias

    Article

    Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.

    Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing

    October 15th 2024

    By Cameron Santoro

    Article

    Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.

    IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics

    October 14th 2024

    By Skylar Jeremias

    Article

    During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.

    From Skepticism to Success: Insights Into Biosimilar Market Acceptance

    October 13th 2024

    By Cameron Santoro

    Video

    Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the US, emphasizing partnerships for market growth.

    Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars

    October 12th 2024

    By Deana Ferreri, PhD

    Article

    A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.

    FDA Approves Imuldosa, a Biosimilar to Stelara

    October 11th 2024

    By Skylar Jeremias

    Article

    Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

    Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share

    October 11th 2024

    By Skylar Jeremias

    Article

    Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.

    The Top 5 Biosimilar Articles for the Week of October 7

    October 11th 2024

    By Cameron Santoro

    Video

    Here are the top 5 biosimilar articles for the week of October 7, 2024.